Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Vonoprazan for Erosive GERD

FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that the U.S....
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news